Sollinda Capital Management’s AbbVie ABBV Stock Holding History

Sollinda Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$632K	Sell	2,511 -33	-1%	-$7.1K	0.13%	41
2026 Q1	$553K	Sell	2,544 -112	-4%	-$24.8K	0.13%	44
2025 Q4	$607K	Sell	2,656 -8	-0.3%	-$1.82K	0.16%	44
2025 Q3	$617K	Sell	2,664 -12,759	-83%	-$2.6M	0.17%	39
2025 Q2	$2.86M	Buy	15,423 +12,407	+411%	+$2.31M	0.75%	17
2025 Q1	$632K	Sell	3,016 -115	-4%	-$22.4K	0.18%	33
2024 Q4	$556K	Buy	3,131 +123	+4%	+$22.6K	0.15%	33
2024 Q3	$594K	Buy	3,008 +49	+2%	+$9.14K	0.17%	34
2024 Q2	$508K	Buy	2,959 +53	+2%	+$8.78K	0.15%	36
2024 Q1	$529K	Sell	2,906 -1,431	-33%	-$247K	0.17%	32
2023 Q4	$672K	Buy	+4,337	New	+$632K	0.19%	30

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sollinda Capital Management's ABBV Position: Q2 2026 in Review

Sollinda Capital Management reduced its AbbVie (ABBV) stake by 1.3% in Q2 2026, selling an estimated $7.1K and leaving 2,511 shares worth $632K. The position accounts for 0.13% of the portfolio, ranked #41.

Sollinda Capital Management first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.86M in Q2 2025. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sollinda Capital Management held 2,511 shares of AbbVie worth $632K as of Q2 2026.
Sollinda Capital Management sold 33 AbbVie shares in Q2 2026, an estimated $7.1K.
AbbVie made up 0.13% of Sollinda Capital Management's portfolio in Q2 2026, its #41 holding.
Sollinda Capital Management first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
Sollinda Capital Management's AbbVie position peaked at $2.86M in Q2 2025.
4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sollinda Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.